Sutro Biopharma Reports 14% Revenue Growth in Q3 2025, Net Loss Increases to $56.9 Million

Sutro Biopharma, Inc. reported its financial results for the third quarter of 2025, revealing a revenue increase of 14% to $9.7 million compared to $8.5 million in the same period last year. For the nine months ended September 30, 2025, total revenue surged by 92% to $90.8 million, up from $47.2 million in the prior year. This growth was primarily driven by a significant increase in revenue from collaboration agreements, particularly with Ipsen, which contributed to a $56.1 million increase in revenue due to the derecognition of deferred revenue following Ipsen's decision not to advance the STRO-003 program.

Despite the revenue growth, Sutro Biopharma reported a net loss of $56.9 million for the third quarter, a 17% increase from the $48.8 million loss in the same quarter of 2024. The nine-month net loss was $144.3 million, a slight improvement from the $155.0 million loss reported in the previous year. The company attributed the losses to high operating expenses, which totaled $58.2 million for the quarter, down 24% from $76.4 million a year earlier, largely due to reduced research and development costs following strategic restructuring efforts.

In March and September 2025, Sutro Biopharma implemented restructuring plans aimed at prioritizing its preclinical programs and reducing operational costs. These plans included a workforce reduction of approximately two-thirds and the decision to exit its internal GMP manufacturing facility by the end of 2025. The restructuring efforts resulted in a reported $9.6 million in restructuring costs for the third quarter, which included severance and clinical trial expenses related to the deprioritization of the luvelta program.

As of September 30, 2025, Sutro Biopharma had cash, cash equivalents, and marketable securities totaling $167.6 million, a decrease from $316.9 million at the end of 2024. The company has an accumulated deficit of $931.2 million and expects to continue incurring significant losses as it advances its research and development activities. Management indicated that the existing capital resources are expected to fund operations for at least the next 12 months, but additional capital will be necessary to support ongoing development efforts.

Looking ahead, Sutro Biopharma plans to focus on its three preclinical antibody-drug conjugate (ADC) programs, with STRO-004 being the highest priority. The company aims to initiate clinical development for STRO-004 by the end of 2025, following the filing and clearance of an Investigational New Drug (IND) application. The company remains committed to exploring partnerships and collaborations to enhance its product development pipeline while managing its operational costs effectively.